Status:
COMPLETED
Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Bloodstream Infection
Sepsis Bacterial
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Bacterial blood stream infections are common and life-threatening. Bloodstream infections have historically been identified using blood cultures, which often take 24-72 hours to result and are imperfe...
Eligibility Criteria
Inclusion
- Patient is located in the Emergency Department at Vanderbilt University Hospital
- ≤ 12 hours from patient presentation to the Emergency Department at Vanderbilt University Hospital
- Age ≥ 18 years
- Clinician has ordered blood cultures
- Clinician has ordered intravenous vancomycin
Exclusion
- Patient is known to be a prisoner
- Patient is known to be pregnant
- Patient is known to have received 2 or more doses of vancomycin since presentation to the Vanderbilt ED
- Patient is known to have a positive bacterial culture in the previous 7 days
- Patient is known to have an infection for which at least 7 days of intravenous vancomycin would routinely be administered regardless of bacterial testing results (e.g., skin and soft tissue infection, etc.)
Key Trial Info
Start Date :
December 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 22 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06069206
Start Date
December 13 2023
End Date
April 22 2025
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37203